Search results
Results from the WOW.Com Content Network
Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa, actively promoting the drug for off-label uses, particularly for the treatment of dementia in the elderly. [258] The $1.415 billion penalty included an $800 million civil settlement, a $515 million criminal fine, and forfeit assets of $100 ...
Eli Lilly (July 8, 1838 – June 6, 1898) was a Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana Light Artillery .
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1 ...
Randall L. Tobias (born March 20, 1942) is an American governmental figure and former chief executive officer of Eli Lilly and Company.A Republican, he was appointed the first United States Director of Foreign Assistance, and served concurrently as the administrator of the U.S. Agency for International Development (USAID), with the rank of ambassador.
Indianapolis-based Eli Lilly (no. 142 on the Fortune 500) is the maker of Mounjaro, classified as Type 2 diabetes drug but which has led to weight loss among patients, and Zepbound, an obesity ...
Articles and categories related to notable people, products, buildings, and events associated with Eli Lilly and Company, a Fortune 500 pharmaceutical company Subcategories This category has the following 2 subcategories, out of 2 total.
Eli Lilly is trading at around 120 times its trailing earnings, while Novo Nordisk is at a price-to-earnings (P/E) ratio of nearly 50. At those kinds of multiples, investors are expecting a lot of ...